Recovery from Bell's palsy after treatment using uncultured umbilical cord-derived mesenchymal stem cells: A case report

Recovery from Bell's palsy after treatment using uncultured umbilical cord-derived mesenchymal stem cells: A case report

Bell's palsy is an idiopathic facial palsy with an unknown cause, and 75% of patients heal spontaneously. However, the other 25% of patients continue experiencing mild or severe disabilities, resulting in a reduced quality of life. Currently, various treatment methods have been developed to tre...

Full description

Saved in:
Bibliographic Details
Published in:World journal of clinical cases Vol. 11; no. 12; pp. 2817 - 2824
Main Authors: Ahn, Hyunjun, Jung, Won-Ju, Lee, Sang Yeon, Lee, Kye-Ho
Format: Journal Article
Language:English
Published: United States Baishideng Publishing Group Inc 26-04-2023
Subjects:
Case Report
Allogenic
Case report
Umbilical cord-mesenchymal stem cells
Bell’s palsy
Facial palsy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bell's palsy is an idiopathic facial palsy with an unknown cause, and 75% of patients heal spontaneously. However, the other 25% of patients continue experiencing mild or severe disabilities, resulting in a reduced quality of life. Currently, various treatment methods have been developed to treat this disease. However, there is controversy regarding their effectiveness, and new alternative treatments are needed. The patient suffered from left-sided facial paralysis due to Bell's palsy for 7 years. The patient received an uncultured umbilical cord-derived mesenchymal stem cell transplant eight times for treatment. After follow-up for 32 mo, the paralysis was cured, and there was no recurrence. Uncultured umbilical cord-derived mesenchymal stem cell transplantation may be a potential treatment for patients with Bell's palsy who do not spontaneously recover.
Bibliography:Author contributions: Ahn H, Jung WJ, Lee SY and Lee KH designed the report; Ahn H and Jung WJ collected the patient’s clinical data; Ahn H and Jung WJ analyzed the data; Ahn H and Lee SY wrote the manuscript; Lee KH provided professional advice and revised the manuscript; all authors issued final approval for the version to be submitted.
Corresponding author: Kye-Ho Lee, PhD, Stem Cell Treatment and Research Institute, bio Beauty and Health Company, 72, UN Village-gil, Yongsan-gu, Seoul 04420, South Korea. khlee@stc365.com
ISSN:2307-8960
2307-8960
DOI:10.12998/wjcc.v11.i12.2817